Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy

뉴스 본문을 불러오고 있어요.

Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy | 웨이프 WAPE

Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy

기사 요약

관련 종목

댓글 —